- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02709174
Pulmonary Embolism in Pregnancy: Biomarkers and Clinical Predictive Models
March 10, 2016 updated by: Barbara Parilla, MD, Advocate Health Care
Diagnosing Pulmonary Embolism in Pregnancy: Are Biomarkers and Clinical Prediction Models Useful?
Objective: To evaluate whether trimester specific d-dimer levels and brain natriuretic protein (BNP), along with the modified Wells score (MWS), is a useful risk stratification tool to exclude pregnant women at low-risk of pulmonary embolism (PE) from diagnostic imaging with radiation exposure.
Study Overview
Detailed Description
To account for all women meeting the study eligibility criteria, this study utilized a combined prospective and retrospective arm.
Pregnant women who underwent diagnostic imaging to evaluate for suspected PE at our institution were prospectively enrolled from February 2014 to August 2015.
Both d-dimer and BNP serum levels were drawn, and a MWS was assigned.
All pregnant women diagnosed with a PE that underwent diagnostic imaging and had a d-dimer level drawn from January 2009 to June 2014 were retrospectively enrolled.
Patient electronic records were used to apply the MWS and analyze their risk.
Study Type
Observational
Enrollment (Actual)
59
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
pregnant women who presented to the Emergency Department or Labor and Delivery unit with signs and symptoms suspicious for PE
Description
Inclusion criteria:
- adult pregnant women >= 18 years old
- d-dimer obtained and if the patient was pregnant at the time of PE diagnosis
- patient presented to the Emergency Department or Labor and Delivery unit
- patient presented with signs and symptoms suspicious for PE
Exclusion criteria:
- non-pregnant patients
- patients < 18 years old
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
pregnant with pulmonary embolism
Pregnant women who underwent diagnostic imaging to evaluate for suspected PE at our institution
|
blood draw
|
pregnant without pulmonary embolism
Pregnant women who underwent diagnostic imaging to evaluate for suspected PE at our institution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum D-dimer levels (ug/ml)
Time Frame: 18 months
|
Trimester specific D-dimer levels to identify pregnant women at low risk for pulmonary embolism, thereby avoiding radiation exposure
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Well's Criteria- a risk scoring system for likelihood of pulmonary embolism
Time Frame: 18 months
|
A Modified Wells score of >4 suggests pulmonary embolism is likely and therefore diagnostic imaging needed
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2014
Primary Completion (Actual)
August 1, 2015
Study Completion (Actual)
August 1, 2015
Study Registration Dates
First Submitted
August 19, 2015
First Submitted That Met QC Criteria
March 10, 2016
First Posted (Estimate)
March 15, 2016
Study Record Updates
Last Update Posted (Estimate)
March 15, 2016
Last Update Submitted That Met QC Criteria
March 10, 2016
Last Verified
March 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB 5699
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Embolism
-
Boston Scientific CorporationEKOS CorporationCompletedPulmonary Embolism | Acute Pulmonary Embolism | Pulmonary Thromboembolism | Massive Pulmonary Embolism | Sub-massive Pulmonary EmbolismUnited States
-
Inari MedicalCompletedPulmonary Embolism | Submassive Pulmonary Embolism | Acute Pulmonary Embolism | Massive Pulmonary EmbolismUnited States
-
University of California, Los AngelesEnrolling by invitationPulmonary Disease | Pulmonary Embolism | Pulmonary Embolus/Emboli | Pulmonary Embolism and Thrombosis | Pulmonary Embolism Subacute Massive | Pulmonary Embolism Acute MassiveUnited States
-
Hospital San Carlos, MadridAsociación de Cardiología Intervencionista de la Sociedad Española de CardiologíaRecruitingPulmonary Embolism | Pulmonary Embolism and Thrombosis | Pulmonary Thromboembolisms | Pulmonary Embolism Acute | Pulmonary Embolism Acute MassiveSpain
-
Inari MedicalActive, not recruitingPE - Pulmonary Embolism | PE - Pulmonary ThromboembolismUnited States, Spain, Belgium, Germany, France, Switzerland, Netherlands, United Kingdom, Austria
-
Victor Tapson, MDBristol-Myers SquibbTerminatedPulmonary Embolism | Right Ventricular Dysfunction | Right Ventricular Failure | Pulmonary Embolism With Acute Cor Pulmonale | Pulmonary Embolism With Pulmonary Infarction | Pulmonary Embolism Subacute MassiveUnited States
-
GlaxoSmithKlineCompleted
-
Bristol-Myers SquibbCompletedPulmonary Embolism (PE) | Pulmonary ThromboembolismUnited Kingdom
-
Sociedad Española de Neumología y Cirugía TorácicaCompletedPulmonary Hypertension | Pulmonary ThromboembolismsSpain
-
Imperative Care, Inc.RecruitingCardiovascular Diseases | Vascular Diseases | Embolism | Thrombosis | Thromboembolism | Acute Pulmonary Embolism | Thrombus; Embolism | Emboli, PulmonaryUnited States
Clinical Trials on blood draw
-
Abbott Point of CareRecruitingPrecision of Potassium (K) Test in Capillary Whole BloodUnited States
-
University Hospital, Strasbourg, FranceNot yet recruitingKidney Transplantation | Humoral Rejection | Kidney Allograft Biopsy | Microvascular Inflammation
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Vanderbilt-Ingram Cancer CenterWren Laboratories LLCCompletedMelanomaUnited States
-
Turtle Health, Inc.Completed
-
National Heart Centre SingaporeDuke-NUS Graduate Medical SchoolRecruiting
-
Duke UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)RecruitingHematologic MalignancyUnited States
-
University of BonnRecruitingSARS-CoV 2 | COVIDGermany
-
Joseph M. Still Research Foundation, Inc.RecruitingInflammatory Response | Deep Vein Thrombosis | Multi Organ Failure | Nosocomial InfectionUnited States